FDA Inspection
Azurity Pharmaceuticals, Inc.Azurity Pharmaceuticals, Inc. – FDA Inspection, Feb 19, 2025
Record Details
This FDA Inspection record concerns Azurity Pharmaceuticals, Inc., with an inspection on February 19, 2025, issued by the New England District Office, covering human drugs.
View Company Profile
ID · 5bc3e1cb-551b-4b19-8657-c5a1e0e2c087
Inspection Facts
- Inspection number
- 1261303
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
1- 21 CFR 211.198(a)Complaint Handling Procedure
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Azurity Pharmaceuticals, Inc.
8| Date | Classification | Office | Project area |
|---|---|---|---|
| December 12, 2025 | NAI | Drug Quality Assurance | |
| March 2, 2023 | Not classified | New England District Office | Drug Quality Assurance |
| February 24, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 26, 2019 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 20, 2017 | Not classified | New England District Office |
Other documents for Azurity Pharmaceuticals, Inc.
- FDA Inspection 1297348 - 2025-12-12
- FDA Inspection 1199279 - 2023-03-02
- FDA Inspection 1163010 - 2022-02-24
- FDA Inspection 1100022 - 2019-07-26
- FDA Inspection 1038444 - 2017-12-20
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.